Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Researchers propose reproducible method to quantify syndesmosis displacement based on spatial WBCT data

The syndesmosis is located just above the ankle where the tibia and fibula meet, providing stability to the ankle joint while allowing for its motion. A sprain, twist, rotational injury, or break to the ankle can stretch and tear the ligaments that support the syndesmosis. Syndesmotic injuries occur in up to 18 percent of all…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The syndesmosis is located just above the ankle where the tibia and fibula meet, providing stability to the ankle joint while allowing for its motion. A sprain, twist, rotational injury, or break to the ankle can stretch and tear the ligaments that support the syndesmosis. Syndesmotic injuries occur in up to 18 percent of all ankle sprains and 23 percent of all ankle fractures. However, the limitations of 2D imaging make a diagnosis and operative treatment of syndesmotic ankle injuries challenging.

Despite high accuracy and sensitivity, CT scans may underestimate the extent of syndesmotic lesions because of non-weight bearing conditions.

Weight bearing cone beam CT (WBCT) is an alternative imaging technique with numerous advantages, including relatively low radiation dose.

Researchers in the United States and Belgium aimed to develop a reproducible method using WBCT to quantify displacement, translation and rotation of the fibula caused by subtle syndesmostic injuries. Current methods use a single slice of a CT volume. The researchers proposed segmenting a volume out of bilateral ankle CTs superimposing the healthy ankle on the contralateral ankle to compare the deviation of the fibula to quantify the extend of the lesion.

The researchers conducted a study on eighteen patients with a unilateral syndesmotic lesion. The results were described in a study titled, “Templating of Syndesmotic Ankle Lesions by Use of 3D Analysis in Weight-bearing and Nonweightbearing CT”.

For those patients with a high ankle sprain (n = 12), bilateral imaging was performed with weight-bearing cone-beam computed tomography (CT), while non-weight-bearing CT was used for those with fracture-associated syndesmotic lesions (n = 6). To quantify the syndesmotic lesions, changes between the most lateral aspect of the lateral malleolus and the anterior and posterior tubercle in the healthy, stationary fibula were compared to those of the affected patients, using a control group of seven studies.

Deviations were calculated using defined anatomical landmarks on computer assisted design (CAD) software, rather than via manual methods.

The study found there were significant differences in the tibiofibular configuration between injured and healthy ankles.

The study concluded that

  • The method was accurate in assessing subtle syndesmotic injuries.
  • In the case of fracture associated with syndesmotic injury, it offered a precise description of the displacement related to the integrity of the distal tibiofibular syndesmosis.
  • In a case with pronounced fibular comminution, the amount of shortening could be preoperatively calculated, facilitating reconstruction of the fibula.

Click here to read about a previous study in which cadavers were scanned via WBCT imaging in an effort to shed light on the rotational dynamics in syndesmosis.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512